Tumour profiling is not the same as inherited-risk testing
Cancer biomarker testing examines genes, proteins or other features of a tumour that may help confirm a subtype, predict whether a treatment could work, explain resistance or identify a clinical-trial option. Testing may use tumour tissue, and selected assays can use circulating tumour DNA from blood.
Somatic tumour testing looks mainly for changes acquired by cancer cells. Germline testing uses blood, saliva or another normal-tissue sample to look for inherited cancer risk. A tumour result can sometimes suggest a possible inherited change, but it does not replace confirmatory germline testing and genetic counselling.
The relevant biomarkers depend on cancer type, stage, previous therapy, specimen quality and the treatment options actually available. A broad panel can still be unhelpful when tissue is poor or the result cannot change the plan.
Who may benefit from review?
Testing is not automatically useful for every person with cancer. It is commonly considered when:.
- A cancer type routinely uses a biomarker to select an approved treatment.
- Disease is advanced, recurrent or resistant and additional treatment options are being evaluated.
- The pathology diagnosis requires molecular clarification or tumour subtyping.
- A clinical trial requires a defined genomic, protein or immune biomarker.
- A prior result may no longer represent the current tumour after progression or treatment.
What the hospital needs to assess
The oncology and pathology teams review the confirmed diagnosis, stage, treatment history, previous biomarker results and the decision the test is expected to inform. A pathologist checks tumour content and sample quality. The laboratory must match the specimen type and assay to the clinical use; a plasma result and a tissue result are not interchangeable in every setting.
Key points for this treatment
From specimen selection to clinical interpretation
The team first chooses the specimen. A recent, representative tumour block may be preferred, while a liquid biopsy can be useful in selected advanced cancers or when tissue cannot be obtained safely. The laboratory may use immunohistochemistry, in-situ hybridization, PCR, next-generation sequencing or another validated method depending on the biomarker.
The report separates detected findings from their clinical interpretation. A biomarker may match an approved therapy, support a clinical trial, predict lack of benefit, or have uncertain significance. The treating clinician must check whether the specific test is validated for the tumour and specimen and whether the linked treatment is approved, available and appropriate.
Results, counselling and next steps
Turnaround begins only after an acceptable specimen reaches the laboratory. Failed quality control, low tumour content, extra pathology review or confirmatory testing can add time. Treatment should not be changed from a portal result before the oncology team explains its evidence level and limitations.
An actionable alteration does not guarantee benefit. Access, contraindications, drug combinations and resistance mechanisms still matter. A variant of uncertain significance should not be treated as a proven target. If a possible inherited alteration is found, confirmatory germline testing and counselling may be recommended for the patient and potentially the family.
Limitations and realistic expectations
Testing can fail or miss alterations because tissue is scant, degraded or has too few tumour cells. A negative liquid biopsy does not always mean the tumour is negative; tissue testing may still be appropriate. Tumours are heterogeneous and change over time, so one sample is a snapshot. Reports may contain uncertain findings, and an apparent treatment match may be off-label, inaccessible or clinically unsuitable.
Do not delay urgent local treatment for a rapidly worsening cancer complication while waiting for broad profiling. The oncology team should decide whether an immediate standard treatment or stabilization must start before results are available.